GlaxoSmithKline Plc said that it has extended its $13 per share cash offer for Human Genome Sciences Inc until 17.00 Eastern Standard Time on 29 June. The tender offer was previously scheduled to expire at midnight on 7 June.
Erytech Pharma SA has received €6.95 million in grants and credits from the French innovation agency, OSEO, to lead a consortium that will investigate new therapies for the enzymatic treatment of chemotherapy or radiotherapy-resistant cancers.
Alize Pharma of France has raised €3.3 million from its existing shareholders to take an experimental product for metabolic disease into a first-in-human study. The study will be carried out in healthy volunteers in 2013.
Genmab A/S is to receive $2 million upfront from Novartis as part of a new collaboration in which the Swiss multinational will use Genmab technology to identify candidate bispecific antibodies against two disease target combinations.
Venture-capital backed Nabriva Therapeutics AG has agreed to sell rights to its lead pleuromutilin antibiotic to Forest Laboratories Inc in exchange for $25 million. Forest also has an exclusive right to buy the company outright within a specified time.
GlaxoSmithKline Plc has told shareholders of Human Genome Sciences that its $13 per share cash offer represents “full and fair value” for the company. The tender will close on 7 June. The HGS board has recommended against the offer.
Cytos Biotechnolgy AG has completed a major portion of a planned CHF 37 million (€30.8 million) equity and debt financing that will give it the resources to conduct a global, multi-centre Phase 2b study of its lead asthma product, CYT003.
GlaxoSmithKline Plc has announced an agreement to fully acquire Cellzome, a specialist in proteomics technology, for £61 million in cash. GSK currently owns 19.98% of the company which is based in Cambridge, UK and Heidelberg, Germany.
Intercell AG has completed a private placement of its shares, raising €15.2 million from the institutional investor BB Biotech, from Novartis, and from a number of other unidentified healthcare investors. The shares were placed at €2.30 per share.
NicOx SA, which is seeking to build an eye-care business after its non-steroidal anti-inflammatory drug for osteoarthritis failed to get regulatory approval, had a profit in the first 2012 quarter due to a milestone from its ophthalmology platform.